Mereo BioPharma Group plc (MREO)
| Market Cap | 341.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.19M |
| Shares Out | 159.00M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 658,257 |
| Open | 2.210 |
| Previous Close | 2.210 |
| Day's Range | 2.110 - 2.220 |
| 52-Week Range | 1.575 - 5.020 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 7.71 (+258.61%) |
| Earnings Date | May 13, 2025 |
About MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MREO stock is "Strong Buy." The 12-month stock price forecast is $7.71, which is an increase of 258.61% from the latest price.
News
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NE...
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...
Mereo BioPharma Provides Update on Lead Clinical Programs
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that...
Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points
Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from ...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that...
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo ...
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in ...
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the ...
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its f...
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively
Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032
Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation th...
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an up...
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...
Mereo BioPharma to Present at the Jefferies Healthcare Conference
LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that ...
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...